Skip to content
Bladder Cancer Updates & SC Amivantamab episode artwork

Dec 18, 2025 13 min

Bladder Cancer Updates & SC Amivantamab

from OncoPharm Hosted by John Bossaer

Are we nearing the end of the Platinum Era in bladder cancer? A press release suggests enfortumab vedotin + pembrolizumab in a perioperative approach is better than the current standard of care: neoadjuvant cisplatin-based chemo followed by surgery. We eagerly await seeing this data. Also, a subcutaneous amivantamab/hyaluronidase formulation is approved, which offers a much lower risk of infusion reactions - but some chances for dosing errors based on weights and available dosage forms.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Bladder Cancer Updates & SC Amivantamab

0:00 13:03

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of OncoPharm?

This episode is 13 minutes long.

When was this OncoPharm episode published?

This episode was published on December 18, 2025.

Can I download this OncoPharm episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.